IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Preliminary results of randomized phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL)
Zhou, C.; Wu, Y.; Chen, G.; Fang, J.; Liu, X.; Wang, C.; Zhang, S.; Wang, J.; Zhou, S.; Ren, S.
刊名JOURNAL OF CLINICAL ONCOLOGY
2010-05-20
suppl.S期:15
收录类别SCI
文章类型Meeting Abstract
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
语种英语
WOS记录号WOS:000208852004708
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54400
专题北京大学临床肿瘤学院
作者单位1.Beijing Chest Hosp, Beijing, Peoples R China
2.Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
3.Jiangsu Prov Canc Hosp, Nanjing, Jiangsu, Peoples R China
4.Tongji Univ, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
5.Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
6.Acad Mil Med Sci, Dept Pulm Oncol, Hosp 307, Ctr Canc, Beijing, Peoples R China
7.Tianjin Canc Hosp, Tianjin, Peoples R China
8.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100871, Peoples R China
9.Tongji Univ, Shanghai Pulm Hosp, Sch Med, Shanghai 200092, Peoples R China
推荐引用方式
GB/T 7714
Zhou, C.,Wu, Y.,Chen, G.,et al. Preliminary results of randomized phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL)[J]. JOURNAL OF CLINICAL ONCOLOGY,2010,suppl.S(15).
APA Zhou, C..,Wu, Y..,Chen, G..,Fang, J..,Liu, X..,...&Ren, S..(2010).Preliminary results of randomized phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL).JOURNAL OF CLINICAL ONCOLOGY,suppl.S(15).
MLA Zhou, C.,et al."Preliminary results of randomized phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL)".JOURNAL OF CLINICAL ONCOLOGY suppl.S.15(2010).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhou, C.]的文章
[Wu, Y.]的文章
[Chen, G.]的文章
百度学术
百度学术中相似的文章
[Zhou, C.]的文章
[Wu, Y.]的文章
[Chen, G.]的文章
必应学术
必应学术中相似的文章
[Zhou, C.]的文章
[Wu, Y.]的文章
[Chen, G.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。